Similarly, Barrow et al found a 10-fold increased risk of prostate cancer associated with MSH2 in study of male Lynch syndrome mutation carriers and their first-degree male relatives who were part of the Manchester Regional Lynch Syndrome database (RR 10.41; 95% CI: 2.80–26.65)89. Here, MSH2 is linked to prostate carcinoma.